Today, we want to tell you about the other three #technology #startup #companies recently added to our portfolio, which highlight the exciting #science you can expose yourself to by investing in our fund. Metacarpal Ltd. The idea here is to design and manufacture a better #prosthetic #hand. Slightly unusually for us, our SEIS investment of approx. £87k (so £43.5k after tax), was part of a larger investment round of £783k. The aim is to finalise the production model and to make initial sales directly to #clinicians in the US. The price of each hand to the end user (typically paid by insurance) is $10,000. MetalloBio. We made an SEIS investment of £55k in this (so £27.5k after tax). This is a restart, following the death from cancer of the young founder, of a business to develop an #antibiotic based on a metal complex, which will be effective against #bacteria which have developed #resistance to existing antibiotics. A key clinical study of 240 clinical isolates involved in complicated urinary tract infections (cUTIs) showed that all of these were susceptible to treatment by Metallobio’s lead compound. The company has recently received notice of the grant of its first patents. Digistain®. We made an SEIS investment of £69,821 (so £35k after tax) to help get this company started. The company offers a service to clinicians to determine whether a patient who has had #breast #cancer #lumps removed would be helped or harmed by post-operative #chemotherapy. Since the investment, the company has had its lab certified (ISO 13845) and has also signed a deal with BUPA to supply its service to BUPA's patients. It has also achieved its first sales which are now growing monthly. In all the above cases, the losses if the companies do not succeed will be small, but the gains if they succeed could run to £ms and will be #taxfree. So please consider #investing in OT(S)EIS. Min £15k. The investments are interesting and we send you a quarterly report with a page of information on each of your investments and a valuation statement. Further steps can be found at https://lnkd.in/ds6CcfT4 and the full risk warnings can be found at https://lnkd.in/eV8yxwey. The risks for each individual investment are high, and if an investment fails, there is unlikely to be any return to investors at all, apart from the initial tax reliefs and also the #lossrelief which can then be claimed against #incometax. But an investment in OT(S)EIS gets you a portfolio of 5 or 6 #SEIS investments so the risk is spread. All investments are GT free after 3 years or IHT free after 2 years so an investment in OT(S)EIS is sensible from a tax planning viewpoint. The ownership of the shares can simply be transferred to heirs and the proceeds of sale can then be paid directly to them. The investments are long-term and the gains up until the date of death are tax free. Additional gains after this will be taxed. But this will be a nice problem to have!
Oxford Technology Management’s Post
More Relevant Posts
-
🚀 Innovation Meets Opportunity: Charles River’s Global Biotech Incubator Program Charles River just launched their Global Biotech Incubator Program (CIP), designed to fast-track innovation by providing startups with the resources, expertise, and global support needed to bring therapies to life. This is a bold step toward empowering the next wave of groundbreaking solutions. #BiotechInnovation #CharlesRiver #GlobalBiotechIncubatorProgram https://lnkd.in/gKAuP_5W
-
🧬 Turning life-changing ideas into successful ventures doesn’t happen overnight—it happens with the right backing. At OcyonBio, we’re here to connect you with the funding to make it happen. Let’s build the future of biotech, together! 💡 #BiotechInnovation #CapitalGrowth #OcyonBio
-
Turning IP into Ventures | Biotech & Digital Innovation | AI-Literate | Translating Science into Opportunity
You’ve made a groundbreaking discovery—but how much is it actually worth? Biotech startups don’t have revenue, yet investors still assign valuations. How? By assessing: ✔ Scientific credibility – Is the discovery real? ✔ Risk reduction milestones – What has been de-risked? ✔ Regulatory & clinical progress – How close is it to approval? ✔ Market potential & partnerships – Who will pay for it? 🚀 So, what’s your startup worth at different stages? 📊 This carousel breaks it down: ✅ Preclinical: $5M-$30M – Based on IP & early data ✅ Phase I: $80M-$200M – First-in-human data boosts valuation ✅ Phase II: $200M-$750M – Partnerships & efficacy drive value ✅ Phase III: $750M-$2B+ – De-risked, close to approval 👇 Swipe through to learn how biotech valuation really works! 💬 What’s your biggest challenge in biotech funding? Let’s discuss! #Biotech #Valuation #StartupFunding #VentureCapital #LifeSciences
-
Founder & Managing Director @ bioCatalyst | Executive Search for Biopharma & TechBio: Partnering, Strategy, Commercial & Operations
"𝐀 𝐓𝐚𝐥𝐞 𝐨𝐟 𝐓𝐰𝐨 𝐒𝐞𝐧𝐭𝐢𝐦𝐞𝐧𝐭𝐬: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 𝐉𝐏𝐌 𝟐𝟎𝟐𝟓" The JP Morgan Healthcare Conference often sets the tone for the year in biotech, offering a glimpse into industry sentiment and emerging trends. This year’s event reflected a mix of optimism and caution. I've come across an insightful piece on LifeSciVC by Aimee Raleigh titled “A Tale of Two Sentiments: JPM 2025” which does a great job of capturing these dynamics shaping 2025 in biotech—highly recommended reading! Here are 3 key takeaways: 1️⃣ Diverging Sentiments: ➔ Private markets are cautiously optimistic, buoyed by successful exits, strategic M&A deals, and resilience in early-stage innovation. ➔ Meanwhile, public markets are struggling with underperforming portfolios, sparking concerns over liquidity and risk appetite. 2️⃣ China’s Growing Influence: ➔ U.S. and European biopharma companies are increasingly licensing assets from China, reflecting its expanding role as a leader in drug discovery and innovation. ➔ This trend is driven by China’s significant investments in R&D and its ability to develop competitive, high-quality assets in areas like oncology, immunology, and advanced biologics, making it an increasingly valuable partner for global collaborations. 3️⃣ A Shift Toward Differentiation: ➔ Investors are showing fatigue with “me-too” programs, prioritizing first-in-class innovation and untapped biological targets that could break new ground. ➔ However, there is a Catch-22: platform and first-in class plays require significant investment and conviction, but early VCs may struggle to back these areas if later-stage investors don't participate in pre-Phase 2 financings. A lack of willingness to take on risk could lead to pipelines lacking novelty in the future. ➔ That said, there are glimmers of change. Recent large follow-on financings for next-gen modalities hint that some investors are beginning to favor riskier but potentially higher-reward biology and deals once again. ➔ There’s also growing interest in novel modalities and approaches that address high unmet needs, particularly in therapeutic areas where conventional methods have struggled to deliver results. ❓For those who attended JPM, how did these themes resonate with your experience? ❓And for my network at large, what are your thoughts on what’s to come in 2025? I’d love to hear your perspectives! For the full article: https://lnkd.in/dupZ_N5N
-
Explore the latest trends in biotech investment where focal shifts towards high-potential companies despite a decrease in the number of deals. This insightful analysis by Brian Gormley on Private Equity News covers the investment landscape for life sciences, noting an increase in the capital allocated to established players within the sectors of cancer and obesity. https://lnkd.in/e_pNKjsT #lifesciences
-
🌐 The Right Resources for Revolutionary Biotech Solutions Biotech is more than discovery; it’s about the right financial support to turn innovation into reality. See how OcyonBio’s capital-raising expertise is helping transform ideas into industry-defining solutions. #WorldChangingScience #CapitalRaising #OcyonBioImpact
-
What does the Fed's rate cut mean for biotech? The biotech industry continues to evolve rapidly, and understanding how rising interest rates impact startups and venture capital is crucial for staying ahead. We’re excited to share a recent article from PharmaVoice that delves into these pressing challenges facing the industry. At AcceleDev, we recognize the importance of adapting to economic shifts and supporting our partners in navigating complex financial and regulatory environments. As thought leaders in custom synthesis and chemistry innovation, we are committed to providing solutions that drive efficiency and value in an ever-changing market. Read the full article here: What the Fed’s rate cut means for biotech | PharmaVoice https://lnkd.in/gBU3ym5d #Biotech #VentureCapital #ThoughtLeadership #PharmaInnovation #AcceleDev #PharmaVoice
-
Biotech Storyteller | Science Communicator | Neuroscience | Pharmacology | Toxicology
The biotech industry's resilience in 2024 is a testament to its ability to adapt and innovate. Despite recent challenges, M&A activity is picking up, IPOs are returning, and investor confidence is rising. It's clear that strategic shifts and consolidation are driving a stronger future for biotech. This is an exciting time for those of us passionate about science and healthcare! Some great insights from BioSpace today! https://lnkd.in/eCwQnJhM #biotech #strategicgrowth #innovation
-
Over the past three days, the Innovation and Investment Zones at #RGMBS2024 have been filled with activity. Founders of startups, biotech innovators, and industry leaders from around the world gathered to showcase cutting-edge innovations, form strategic partnerships, and explore the future of medical biotechnology. The energy and engagement of participants were clear as they connected with investors and exchanged insights that will shape the path forward in biotech. RGMBS2024 has truly underscored the power of collaboration in advancing healthcare and fostering transformative solutions. #Biotech #Innovation #Investment #RGMBS2024
-
🌟 Attention Biotech and Venture Capital Leaders 🌟 This morning, I picked up the #NVCA Quarterly report (1Q'24) for some reference data and came across a statement that made me pause: “However, many biopharma startups are pre-revenue and need to burn a significant amount of capital while making advances clinically.” While this statement is factual, it opens up significant opportunities for interpretation and, more importantly, ACTION. Today, I pose the following questions to our community: 💰 Investors: Besides leveraging AI what steps are you taking to support emerging biopharma companies through this historically challenging paradigm? 🕴 Biopharma Executives: Have you considered adopting an alternate business model to sustain the biotech business? At #UbuntuResearch, we have a unique perspective based on our current work, but I would love to hear from the community. Let’s engage meaningfully to address the complex issue of biotech financing. How can we collaborate to find innovative solutions? Source: Venture Monitor - Q12024 #Biotech #VentureCapital #GlobalDrugDevelopment #UbuntuResearch #BiotechExec
